Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis

被引：1

作者：

Ochi, S

Nanki, T

Takada, K

Suzuki, R

Komano, Y

Kubota, T

Miyasaka, N

机构：

[1] Tokyo Med & Dent Univ, Grad Sch, Dept Med & Rheumatol, Bunkyo Ku, Tokyo 1138519, Japan

[2] Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Tokyo 1138519, Japan

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2005年 / 23卷 / 05期

关键词：

polymyositis; dermatomyositis; interstitial lung disease; tacrolimus;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Two cases of progressive interstitial lung disease associated with polymyositis/dermatomyositis are presented. Both patients were refractory to conventional therapy with high-dose corticosteroids, cyclosporine, and intermittent pulse cyclophosphamide, and thus a therapeutic trial of tacrolimus was instituted. Tacrolimus was markedly effective in achieving subjective, laboratory and radiographic improvement in both patients.

引用

页码：707 / 710

页数：4

共 50 条

[31] The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review
Yongpeng Ge
Hang Zhou
Jingli Shi
Bin Ye
Qinglin Peng
Xin Lu
Guochun Wang
Clinical Rheumatology, 2015, 34 : 2097 - 2103
[32] KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis
Fathi, M.
Helmers, S. Barbasso
Lundberg, I. E.
JOURNAL OF INTERNAL MEDICINE, 2012, 271 (06) : 589 - 597
[33] Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis
Huh, Jin Won
Kim, Dong Soon
Lee, Chang Keun
Yoo, Bin
Seo, Joon Bum
Kitaichi, Masanori
Colby, Thomas V.
RESPIRATORY MEDICINE, 2007, 101 (08) : 1761 - 1769
[34] miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease
Sugiyama, Yumiko
Yoshimi, Ryusuke
Takeno, Mitsuhiro
Kunishita, Yosuke
Kishimoto, Daiga
Kamiyama, Reikou
Kirino, Yohei
Ohno, Shigeru
Nakajima, Hideaki
MODERN RHEUMATOLOGY, 2020, 30 (05) : 878 - 883
[35] Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease
Hozumi, Hironao
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakashima, Ran
Enomoto, Yasunori
Suzuki, Yuzo
Kono, Masato
Karayama, Masato
Furuhashi, Kazuki
Murakami, Akihiro
Inui, Naoki
Nakamura, Yutaro
Mimori, Tsuneyo
Suda, Takafumi
JOURNAL OF RHEUMATOLOGY, 2017, 44 (09) : 1394 - 1401
[36] Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease
Li, Liubing
Wang, Han
Wang, Qian
Wu, Chanyuan
Liu, Chenxi
Zhang, Yanfang
Cheng, Linlin
Zeng, Xiaofeng
Zhang, Fengchun
Li, Yongzhe
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 397 : 123 - 128
[37] Polymyositis/dermatomyositis-associated lung disease:: analysis of a series of 81 patients
Selva-O'Callaghan, A
Labrador-Horrillo, M
Muñoz-Gall, X
Martínez-Gómez, X
Majó-Masferrer, J
Solans-Laque, R
Simeon-Aznar, CP
Morell-Brotard, F
Vilardell-Tarrés, M
LUPUS, 2005, 14 (07) : 534 - 542
[38] Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease
Gui, Xianhua
Li, Wangzhong
Jiang, Hanyi
Wang, Rujia
Yu, Min
Zhao, Tingting
Ma, Miao
Ding, Jingjing
Jin, Ziyi
Qiu, Yuying
Qiu, Xiaohua
Zhang, Yingwei
Cao, Min
Huang, Mei
Cao, Mengshu
Dai, Jinghong
Cai, Hourong
Xin, Xiaoyan
Xiao, Yonglong
RMD OPEN, 2024, 10 (02):
[39] A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis
Mira-Avendano, Isabel C.
Parambil, Joseph G.
Yadav, Ruchi
Arrossi, Valeria
Xu, Meng
Chapman, Jeffrey T.
Culver, Daniel A.
RESPIRATORY MEDICINE, 2013, 107 (06) : 890 - 896
[40] Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study
Nakazawa, Maho
Kaneko, Yuko
Takeuchi, Tsutomu
CLINICAL RHEUMATOLOGY, 2018, 37 (03) : 765 - 771

← 1 2 3 4 5 →